Moreover, a proteasome inhibitor Bortezomib (also known as Velcade or PS-341) that targets ubiquitin-proteasome system has been approved for the treatment of multiple myeloma and mantle cell lymphoma, and a small molecule MLN4924 that attenuates Cullin activity has entered phase I clinical trials for haematological and solid tumour malignancies 25,26. The gene discussed is CACUL1; the disease is mantle cell lymphoma.